References
- Bosl GJ, Gluckman R, Geller N, et al. VAB-6: An effective chemotherapy regimen for patients with germ cell tumors. J Clin Oncol 1986; 4: 1493–1499
- Williams S, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin. bleomycin and either vin-blastine oretoposide. N Engl J Med 1987; 316: 1435–1440
- Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide + cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990; 66: 2476–2481
- Einhorn LH, Weathers T, Loehrer P, et al. Second line chemotherapy with vinblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin. VP-16 and bleomycin (PVP16B) in disseminated germ cell tumors (GCT): Long term followup. Proc Am Soc Clin Oncol 1992; 11: 196, abstract 599
- Motzer R, Geller N, Bajorin D, et al. Salvage chemotherapy for patients with germ cell tumors: The Memorial Sloan-Kettering Cancer experience (1979-1989). Cancer 1991; 67: 1305–1310
- Motzer RJ, Bajorin DF, Bosl GJ. Poor-risk germ cell tumors: current progress and future directions. Semin Oncol 1992; 19: 206–214
- Toner GJ, Geller NL, Tan C, et al. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50: 5904–5910
- Murphy BA, Motzer RJ, Mazumdar M, et al. Serum marker decline during ifosfamide-salvage therapy predicts event-free and overall survival in germ cell tumor patients. Proc Am Assoc Cancer Res 1992; 33: 205, abstract C-1230
- Motzer RJ, Gulati SC, Crown J, et al. High dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors; early intervention is better tolerated. Cancer 1992; 69: 550–556
- Nichols C, Tricot G, Williams S, et al. Dose-intensive chemo therapy in refractory germ cell cancer—A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932–939
- Nichols CR, Andersen Lazarus HM, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory ger cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10: 558–563
- Blijham G, Spitzer G, Litam J, et al. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer 1981; 17: 433–441
- Linkesch W, Krainer M, Wagner A. Phase I/II trial of ultrahigh dose carboplatin. etoposide, cyclophosphamide with ABMT in refractory or relapsed germ cell tumors (GCT). Proc Am Soc Clin Oncol 1992; 11: 196, abstract C-600
- Murphy BA, Motzer RJ, Bosl GJ. Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in germ cell tumors. Invest New Drugs, in press